Experimental Surgery Denied by Insurance: Appeal

"Experimental" and "investigational" are among the most powerful words in an insurer's denial vocabulary. Once a procedure is labeled either, coverage is typically excluded outright. But these labels are applied inconsistently — sometimes to procedures that have been standard of care for years. Here is how to challenge an experimental or investigational surgery denial.

How Insurers Decide What Is "Experimental"

Most insurers maintain a list of procedures they consider experimental or investigational, updated periodically by their internal technology assessment committees. However, these determinations often lag behind medical practice and published evidence by years.

Insurers typically look at:

• FDA approval status (but FDA approval is not required for medical coverage — many surgical procedures are never FDA-approved because they involve physician technique, not a device)
• Whether the procedure has "well-designed clinical trials" demonstrating effectiveness
• Whether professional medical societies endorse the procedure
• Whether there is a consensus in the peer-reviewed literature

A procedure can be denied as investigational even when it has Level A evidence in peer-reviewed journals, is endorsed by major specialty societies, and is routinely performed at academic medical centers nationwide.

Robotic Surgery: No Longer Experimental

Robotic-assisted surgery using the da Vinci system and similar platforms has been used in urology, gynecology, thoracic surgery, and general surgery for over two decades. The clinical evidence base is extensive. Robotic prostatectomy, robotic hysterectomy, and robotic-assisted lobectomy are standard procedures at most major hospitals.

If your robotic surgery was denied as "experimental," this is almost certainly incorrect. Your appeal should include:

• Published clinical guidelines from the relevant specialty society (AUA, ACOG, STS, etc.) endorsing robotic assistance
• Peer-reviewed studies demonstrating equivalent or superior outcomes compared to open surgery
• Documentation that your surgeon and facility have significant experience with the robotic procedure (reduces "experimental" characterization)

Emerging Procedures With Strong Evidence

Several newer cardiovascular procedures are frequently denied as investigational despite robust clinical evidence:

TAVR (Transcatheter Aortic Valve Replacement): FDA-approved and endorsed by the American College of Cardiology (ACC) and American Heart Association (AHA) for aortic stenosis across all surgical risk levels. If denied, cite ACC/AHA guidelines and the FDA approval date.

WATCHMAN Device (Left Atrial Appendage Closure): FDA-approved for non-valvular atrial fibrillation as an alternative to long-term anticoagulation. Covered by Medicare. If denied by private insurance, cite FDA approval and CMS national coverage determination.

MitraClip (Transcatheter Mitral Valve Repair): FDA-approved for certain patients with mitral regurgitation. ACC/AHA guidelines support use.

If your procedure is FDA-approved and endorsed by a major cardiovascular specialty society, an "experimental" denial is highly likely to be overturned on appeal.

How to Build a Strong Appeal

Step 1: Request the insurer's technology assessment or coverage policy. Your insurer has an internal document justifying the experimental classification. Request it. Compare their evidence sources to current peer-reviewed literature.

Step 2: Gather peer-reviewed evidence. PubMed (pubmed.ncbi.nlm.nih.gov) is free and searchable. Look for:

• Randomized controlled trials or large prospective cohort studies
• Meta-analyses showing effectiveness
• Evidence published within the last 5 years that the insurer may not have reviewed

Step 3: Obtain specialty society endorsements. Letters or guidelines from professional organizations (ACC, AHA, ACS, AUA, ACOG, etc.) carry significant weight.

Step 4: Get a letter from your surgeon. Your surgeon should specifically address:

• The clinical appropriateness of this procedure for your specific condition
• The established evidence base for the procedure
• Why alternatives are inadequate or contraindicated for you
• The surgeon's and facility's experience with the procedure

Step 5: Request a peer-to-peer review. Your surgeon speaking directly with the insurer's medical director is often effective — a physician conversation about the clinical evidence is harder to dismiss than a written letter.

Step 6: Write the appeal letter. Specifically contest the "experimental" classification by:

• Citing FDA approval status if applicable
• Citing CMS (Medicare) coverage determinations — if Medicare covers it, insurers have difficulty arguing it is truly experimental
• Listing peer-reviewed studies supporting the procedure
• Including specialty society guidelines endorsing the procedure
• Addressing each of the insurer's stated criteria for the experimental determination

Step 7: External Independent Review: Complete Guide" class="auto-link">External review. If internal appeal fails, external review is conducted by independent physicians who apply accepted clinical standards. Experimental/investigational denials for FDA-approved or evidence-based procedures are frequently overturned at external review.

When the Procedure Is Genuinely New

If the procedure is truly new (performed in fewer trials, limited outcome data), your appeal is harder but not impossible. Focus on:

• Your specific condition and why standard alternatives have failed or are contraindicated
• Compassionate use or right-to-try arguments if applicable
• Whether your state insurance commissioner has issued guidance on coverage for this procedure

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal